NEW YORK (GenomeWeb) – Cenix Biosciences this week announced that it has signed an agreement to provide RNAi-based high-content screening services to Germany's Bayer Pharma.
Cenix said the deal relates to a target discovery project for an undisclosed disease indication. Financial terms were not disclosed.